By providing reliable and accurate medical services to patients, CGBIO counts on stronger business competitiveness in digital healthcare.

The funds will be used to further develop the company’s core algorithmic innovations and to advance its growing life sciences businesses.

This financing further validates the significant advances in our AI discovery platform and growth of our proprietary preclinical pipeline.

The investment will help the company accelerate the development of its predictive analytics platform.

“Wound care is a space that has been void of innovation for so long,”

Valo is building a fully-integrated, end-to-end approach to developing drugs from discovery through approval.

“Robotics-driven digital surgery is clearly a rising trend for MIS, with great market potential and tremendous room for innovation...

The platform combines human expertise with the power of augmented reality (AR), machine learning (ML), artificial intelligence (AI)...

This process is an innovation killer, making it difficult for small laboratories to do drug research and even discouraging large pharma...

Sonavi Labs deploys Feelix—an advanced, objective analytics software platform—into hardware to help physicians deliver...

'Pepticom, a leader in artificial intelligence peptide drug design and discovery, announced today that it has raised $2.6 million to...

"Two Taiwanese Biotechnology Companies, VIRTUALMAN and Hughes Biotechnology, Speed Up and Optimize R&D Processes with Innovative...

Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital Medicine Executive...